Department of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Biomed Pharmacother. 2022 Feb;146:112491. doi: 10.1016/j.biopha.2021.112491. Epub 2021 Dec 9.
Accumulating studies revealed that 6-gingerol, a compound extracted mainly from ginger, treats obesity by preventing hyperlipidemia in vivo induced by high-fat-diet (HFD). The present study intends to further evaluate the efficacy of 6-gingerol in the treatment of obesity and investigate its potential mechanism.
Obese mice were established by HFD induction. Bioinformatic analysis was used to predict the possible pathways enrolled by the application of 6-gingerol. Body weight and the levels of blood glucose and lipids were examined and analyzed for the evaluation of the therapeutic effect of 6-gingerol. The size and amounts as well as the status of adipocytes were determined by histological staining. The expression levels of related proteins in adipose tissue were assessed by immunohistochemical staining, immunofluorescent staining, and Western blot analysis. In addition, the expression levels of related mRNA were assessed by RT-qPCR.
HFD induced obesity was significantly curbed by 6-gingerol treatment. Here inhibition mechanism of 6-gingerol is demonstrated on excessive hypertrophy and hyperplasia of adipocytes in white adipose tissue (WAT), which may be related to the regulation of adipocytokines, such as PPARγ, C/EBPα, FABP4 and adiponectin, and the TLR3/IL-6/JAK1/STAT3 axis. Moreover, 6-gingerol treatment suppressed the expressions of IL-1β and CD68 in the liver and AKT/INSR/IRS-1 in epididymal WAT.
The results suggested that 6-gingerol could alleviate metabolic inflammation in the liver and insulin resistance to treat obesity. The mechanism is mainly involved in the inhibition of excessive hypertrophy and hyperplasia of adipocytes.
越来越多的研究表明，6-姜酚是一种主要从生姜中提取的化合物，通过预防高脂肪饮食（HFD）诱导的体内高血脂，可用于治疗肥胖症。本研究旨在进一步评估 6-姜酚治疗肥胖症的疗效，并探讨其潜在机制。
通过 HFD 诱导建立肥胖小鼠模型。采用生物信息学分析预测 6-姜酚作用的可能途径。检测和分析体重、血糖和血脂水平，评估 6-姜酚的治疗效果。通过组织学染色测定脂肪组织中脂肪细胞的大小、数量和状态。通过免疫组化染色、免疫荧光染色和 Western blot 分析评估脂肪组织中相关蛋白的表达水平。此外，通过 RT-qPCR 评估相关 mRNA 的表达水平。
6-姜酚治疗显著抑制了 HFD 诱导的肥胖。本研究揭示了 6-姜酚抑制白色脂肪组织（WAT）中脂肪细胞过度肥大和增生的作用机制，可能与调节脂肪细胞因子（如 PPARγ、C/EBPα、FABP4 和脂联素）和 TLR3/IL-6/JAK1/STAT3 轴有关。此外，6-姜酚治疗还抑制了肝脏中 IL-1β 和 CD68 以及附睾 WAT 中 AKT/INSR/IRS-1 的表达。
结果表明，6-姜酚可减轻肝脏代谢炎症和胰岛素抵抗，从而治疗肥胖症。其机制主要涉及抑制脂肪细胞过度肥大和增生。
